Hypersensitivity syndrome associated with dapsone/pyrimethamine (Maloprim) antimalaria chemoprophylaxis

Annals of Allergy, Asthma and Immunology

Volumn 88, Issue 5, 2002, Pages 527-529

  Thong, Bernard Yu Hor ^a   Leong, Khai Pang ^a   Chng, Hiok Hee ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MALOPRIM; PREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; CHEEK MUCOSA EROSION; CHEMOPROPHYLAXIS; CHILL; CLINICAL FEATURE; COOMBS TEST; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEVER; GLANS MUCOSA EROSION; HEMOLYTIC ANEMIA; HEPATITIS; HEPATOSPLENOMEGALY; HUMAN; LYMPHADENOPATHY; MALE; MOUTH DISEASE; MOUTH ULCER; PENIS DISEASE; PRIORITY JOURNAL; RASH; SINGAPORE; SOLDIER; SYMPTOM;

EID: 0036590771     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62394-0     Document Type: Article

References (19)

1. Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986;35:451-458.
2. Curley RK, Macfarlane AW. Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine. Br Med J (Clin Res Ed) 1985;290:471-472.
3. Fansidar-associated fatal reaction in an HIV-infected man. MMWR Morb Mortal Wkly Rep 1988;37:571-572, 577.
4. Kimura S, Oka S, Mohri H, et al. Three cases of acquired immunodeficiency syndrome complicated with toxic epidermal necrolysis. Jpn J Med 1991;30:553-558.
5. Raviglione MC, Dinan WA, PablosMendez A, et al. Fatal toxic epidermal necrolysis during prophylaxis with pyrimethamine and sulfadoxine in a human immunodeficiency virus-infected person. Arch Intern Med 1988;148:2683-2685.
6. Daniel PT, Holzschuh J, Berg PA. Sulfadoxine specific lymphocyte transformation in a patient with eosinophilic pneumonia induced by sulfadoxinepyrimethamine (Fansidar). Thorax 1989;44:307-309.
7. Grayson ML, Yung AP, Doherty RR. Severe dapsone syndrome due to weekly maloprim. Lancet 1988;1:531.
8. Johnson DA, Cattau EL Jr, Kuritsky JN, Zimmerman HJ. Liver involvement in the sulfone syndrome. Arch Intern Med 1986;146:875-877.
9. Kumar RH, Kumar MV, Thappa DM. Dapsone syndrome-a five year retrospective analysis. Indian J Lepr 1998;70:271-276.
10. Chan HL, Lee KO. Tonsillar membrane in the DDS (dapsone) syndrome. Int J Dermatol 1991;30:216-217.
11. Gupta A, Eggo MC, Uetrecht JP, et al. Dapsone-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992;51:56-67.
12. Guo R, Thormann W, Lauterberg B. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. Chin Med J 1996;109:933-936.
13. Saito S, Ikezawa Z, Miyamoto H, Kim S. A case of the "dapsone syndrome." Clin Exp Dermatol 1994;19:152-156.
14. Jamrozik K. Dapsone syndrome occurring in two brothers. Lepr Rev 1996;57:57-62.
15. Roujeau JC. Treatment of severe drug eruptions. J Dermatol 1999;26:718-722.
16. Chalasani P, Baffoe-Bonnie H, Jurado RL. Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. South Med J 1994;87:1145-1146.
17. Caumes E, Bocquet H, Guermonprez G, et al. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Clin Infect Dis 1995;21:656-658.
18. Piketty C, Weiss L, Picard-Dahan C, et al. Toxic dermatitis caused by pyrimethamine in patients with acquired immunodeficiency virus infection [in French]. Presse Med 1995;24:1710.
19. Costello JM, Becroft DM. Drug reaction simulating malignant lymphoma: a case due to pyrimethamine. N Z Med J 1977;86:430-432.